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currently used agents, strategies such as cost-sharing to encourage payers to think 
beyond the price tag, and promoting familiarity with novel agents among regional 
and local payers will help optimize the market access opportunity.
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Objectives: The objective of the analysis was to assess the pricing and reimburse-
ment possibilities, as well as the budget impact, of a new medicine for bladder 
cancer immunotherapy. MethOds: We investigated the number of medicines 
for bladder cancer immunotherapy that were registered and listed in the period 
between March 2011 and March 2014, in Serbia. We also made pharmacoeco-
nomics analysis that would be a part of the Health Insurance Fund submission 
file. Results: According to the European Association of Urology (EAU) Guidelines 
for non-muscle invasive bladder cancer (NMIBC) there are several bladder preser-
vation strategies available: intravesical immunotherapy, intravesical chemother-
apy, device-assisted therapy and combination therapy. In Serbia, there are three 
medicines listed for chemotherapy (doxorubicin, epirubicin and mitomycin) and 
one for intravesical immunotherapy (BCG). BCG has become the standard of care 
for high-grade NMIBC and carcinoma in-situ (CIS) and is superior to intravesical 
chemotherapy in reducing recurrences, in preventing or delaying progression of the 
disease. Radical cystectomy should be considered after BCG treatment failure, when 
BCG is contraindicated or not available. BCG is reimbursed in Serbia (wholesale 
price: 79,18€ ) but due to continuous shortages of registered BCG from May 2012, 
non-registered BCG was also listed (price: not defined). Still there was no import, 
due to worldwide shortages. The absence of the treatment encouraged the Serbian 
Institute of Virology, Vaccines and Sera “Torlak” to develop BCG for immunotherapy. 
As the price proposal for new medicine would be 55,43€ , expenses per patient per 
year would be 498,87€ and total costs for 520 patients would be 259.412,40€ , it is 
projected that total savings would be 111.150,00€ per year. Market share of domestic 
BCG would be 0,29% of total B list (hospital medicines) budget. cOnclusiOns: The 
future aim is to develop, register and list domestic BCG that would provide lower 
costs per patient, high quality, availability and the continuous immunotherapy.
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Objectives: To provide a better understanding of: how changes in the use of an 
oncology medicine can affect its aggregate value; how different HTA systems have 
assessed these value expansions; and whether there is a link between value expan-
sions and use. MethOds: We examine all oncology medicines approved by the 
EMA between 2003 and 2005 – giving a sample of 10 medicines. Our framework sets 
out seven possible value expansions beyond an initial approved indication: differ-
ent cancer type; different disease stage; different treatment line/stage; different 
treatment regimen; orphan designation; patient sub-population; and new route of 
administration. We then assessed how HAS (France), NICE (England and Wales), and 
Aetna (US) have recognised these value expansions. Finally, we analysed IMS data 
(2004-2013) on prices, volumes and sales for the five of the medicines. Results: 
Seven of the 10 medicines in the sample have additional value expansions following 
initial indication. Many are now used for indications that are very different from 
their original indication. Most of the HAS assessments resulted in the drug being 
reimbursed but the rewards to the manufacturers were in many cases relatively low 
because few of the recommended drugs were given low “improvement in medical 
service” (ASMR) levels. The majority of NICE appraisals (63%) resulted in the drug/
indication not being recommended for use in the NHS. Generally, the UK had lower 
prices, volumes and sales than France and the US (with some exceptions). The 
comparisons between France and the US were a little more equivocal. There is a 
mixed picture in terms of the correlation between NICE/HAS recommendations and 
sales in the UK/France. We observe a link between expansions in licensed indica-
tions and changes in sales. cOnclusiOns: Health systems and policy makers need 
to recognise how product life-cycle considerations affect the value of medicines, 
and in particular, oncology medicines.
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Objectives: In December 2011, a threshold value of costs/QALY was introduced 
to Slovak legislation. The aim of this work is to assess its impact on inclusion of 
oncology drugs to the reimbursement system and their availability in clinical 
practice. MethOds: We evaluated the inclusion of oncology drugs to the reim-
bursement system based on data from the website of the Ministry of Health SR. 
We analysed the consumption of drugs based on the National Health Information 
Centre database. We acquired information about registered oncology drugs on the 
EMA website. We determined the level of availability of oncology drugs in clini-
cal practice via a qualitative survey among oncologists. Results: The success 
rate of including new oncology drugs in Slovakia was high in 2000-2011. From the 
62 oncology drugs registered in this period by the EMA, 48 were included to the 
Reimbursement List. Innovative oncology drugs were included relatively quickly 
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Objectives: In recent years (2011-2014) various new oncology therapies were 
launched and evaluated by the different market access authorities. The interna-
tional Prismaccess database includes all evaluations and decisions by the respec-
tive authorities in France, Germany and the UK. MethOds: All decisions for new 
oncology therapies which were evaluated by the authorities in France, Germany 
and UK were systematically searched for. A comparison was executed with a 
focus on reimbursement decision, basis of decision, acceptance of submitted 
clinical endpoints, study designs, comparator, quality of life and indirect treat-
ment comparison (ITC). Results: In total there were 23 new oncology therapies 
being evaluated in the three countries. In France 10 decisions were positive (ASMR 
I-III), further 6 of minor improvement (ASMR IV), 20 were positive in Germany 
(n= 3 ‘significant’; n= 6 ‘considerable’; n= 9 ‘minor’; n= 2 ‘non-quantifiable’ added 
benefit) and 4 were positive in England and 5 in Scotland. In 2 cases, respectively 
the assessment was positive (different magnitude) or negative in all countries. 
26% (n= 6) it was similar in at least three countries. (n= 5 positive decisions; n= 1 
negative decision). In case overall survival was the primary endpoint the likeli-
hood was higher in all countries for a positive decision. Key differences in terms 
of decisions were given in acceptance of ITCs, comparator as standard of care and 
ratings for cost-effectiveness. cOnclusiOns: Using the Prismaccess database the 
analysis shows that there might be key differences in terms of evaluation criteria 
between the three countries analysed. In Germany a key focus is given on the 
appropriate comparator(s) and patient-relevant endpoints. In the UK and Scotland 
cost-effectiveness might trump a positive benefit assessment. In France the key 
drivers are not only the severity of the pathology (for tumours, 25% of SMR are not 
substantial), but also efficacy/adverse events ratio, Effective amount, Comparator 
choice and Therapeutic strategy.
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Objectives: Korean government has been making efforts to improve the access 
of orphan drugs or cancer drugs to patients since it is difficult for these drugs 
to be reimbursed due to its high price or lack of clinical evidence. We aim to 
investigate the current status of reimbursement and reviewed related schemes 
in Korea. MethOds: Appraisal results for orphan or cancer drugs during 7 years 
(2007~2013) were included and recommendation rate, final listing rate and order of 
entry among 8 countries were analyzed. Results:  Total 331 were recommended to 
be reimbursed in overall 467 appraisal results (71%), whereas 74 was recommended 
to be reimbursed among 121 results for orphan or cancer drugs (61%), indicating 
that it was less likely to be recommended for those drugs. Fifty eight orphan or 
cancer drugs (48%) were finally listed through NHIC negotiation process. For cancer 
drugs, recommendation and listing rate seem to increase from 47% to 64% and 32% 
to 48% (2008~2010 vs 2011~2013), respectively. Those drugs have been reimbursed 
in the 4.86th place among 8 countries including Korea on the average. Besides, 15 
drugs considered as rule of rescue in those drugs have been listed for reimburse-
ment. cOnclusiOns: We identified that orphan or cancer drugs has been more 
accessible to patients as time goes. As the benefit enhancement plan for four major 
diseases (2013) and the Risk Sharing scheme (2013) have been implemented, it is 
expected for the coverage for those drugs in Korean National Health Insurance to 
be widened through these schemes.
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Objectives: Health technology assessment (HTA), pricing and reimbursement 
(P&R) processes, and cost-containment strategies in France, Germany, Italy, Spain, 
and the UK, are increasingly stringent. This study explored the resulting impact on 
high-cost oncology brands, and carved out specific market access levers and barri-
ers. MethOds: Across the EU5, 500 medical or hematological oncologists were sur-
veyed regarding their current and expected prescribing patterns, and 30 payers who 
influence reimbursement at national or regional level were interviewed. Results: 
Some 68-83% of surveyed oncologists in France, Italy, Spain, and the UK, and 44% 
in Germany report that the average time taken by their health care authority to 
review newly approved cancer treatments and settle reimbursement terms delays 
availability for prescribing by ≥ 6 months. Thereafter, country-specific prescribing 
restrictions impede uptake; e.g., 18% of German hematologists surveyed report 
that their indicative prescribing budget prevents use of ponatinib in > 20% of their 
chronic myeloid leukemia patients, while 30% of Italian medical oncologists say the 
national oncology drugs register monitoring use of costly agents severely restricts 
prescribing of erlotinib and gefitinib for non-small-cell lung cancer. Interviewed 
payers stress, however, that well-designed pivotal trials considering increasing focus 
on added benefit over direct comparators will help optimize HTA and P&R terms, 
with those in Italy and the UK, especially, advocating cost-sharing schemes to secure 
market entry. Furthermore, demonstrable downstream cost savings, locally targeted 
marketing campaigns, and manufacturer estimates of patient population size to aid 
regional/local budget planning are specified as uptake levers. cOnclusiOns: HTA 
and P&R demands and tightening budgets negatively impact prescribing of costly 
oncology brands in the EU5. However, clear demonstration of robust benefits over 
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ric cancers. MethOds: Current oncology PIPs were manually extracted from the 
EMA website for the study period 2007-2014. Primary variables included: indication, 
applicant, decision, decision date, and date of expected completion. Indications for 
approved PIPs were classified into five categories: brain tumors, diagnostics, leuke-
mias/lymphomas, side effects, and solid tumors. Results: A total of 105 PIPs were 
found; 36 of which were waivers, and 69 of which were approved. The study found 
that 39% (27) of approved PIPs were indicated for solid tumors, including melanomas 
and malignant tumors; 30% (21) of approved PIPs were indicated for leukemias or 
lymphomas; 17% (12) of approved PIPs were indicated for chemotherapy-induced 
side effects, such as anti-nausea and neuotropenia medications; 12% (8) of approved 
PIPs were indicated for brain tumors; and one oncology diagnostic PIP was also 
approved. The ramp-up of the PIP program was significant. PIPs approved in 2013 
and the first half of 2014 accounted for 54% (37) of all PIPs approved during the study 
period. cOnclusiOns: Approved PIPs covered a wide range of pediatric cancers, 
and the number of approved PIPs increased significantly over time. While the ramp-
up of the PIP program indicated that it was successful in promoting research in 
this area, serious concerns remained regarding the feasibility of the program. For 
example, there were currently four trials planned for completion between 2015-
2020 for extremely rare high grade gliomas. This limitation may compromise the 
integrity of the PIP program.
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Objectives: Little information is available on the patterns of chemotherapy regi-
mens administered for the treatment of ovarian cancer (OC) in the Netherlands. 
The objective for this study was to describe current chemotherapy patterns for OC 
in the Netherlands and to evaluate survival outcomes following subsequent lines 
of chemotherapy. MethOds: Data from the Eindhoven Cancer Registry, including 
data on all newly diagnosed cancer patients, was linked to the PHARMO Database 
Network including, among other things, information on in- and outpatient drug use. 
Patients diagnosed with primary OC between January 2000 and December 2010 were 
selected. First and subsequent chemotherapy regimens were defined as the start of 
a different (combination of) chemotherapeutic agent (s) or a gap > 42 days (or > 91 
or > 183 days in sensitivity analysis) between two treatment cycles. Results: Of 
the included OC patients, 70% received chemotherapy as initial treatment. Detailed 
chemotherapy data were available for 261 patients, who had a mean age of 63 (SD 
12) years. Pathological tumor stage was known for 77% of patients, of whom 11%, 
55% and 17% of patients had disease stage II, III, and IV, respectively. In first line 
chemotherapy, 76% of patients received platinum/taxane doublet chemotherapy. 
Of the 161 patients receiving second line chemotherapy, platinum-containing 
chemotherapy was received by 63% of patients (101 of whom 13 received platinum 
monotherapy). In third line chemotherapy this was 51% (53 patients). At least eight 
lines of chemotherapy were identified in 12 cases. Median survival as from diag-
nosis was 46 months. After second line chemotherapy, median survival remained 
14 months. cOnclusiOns: This study provides detailed information on the type 
of chemotherapy regimens administered to OC patients at initial diagnosis and 
during follow-up and the survival following the various chemotherapy regimens.
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Objectives: Erythropoietin stimulating agents (ESAs) are useful drugs for treating 
chemotherapy related anemia to reduce the number of blood transfusions. However, 
there were unrecognized toxicities of ESAs. These toxicities were finally recognized 
in 2007 when the FDA issued a black box warning for ESAs. The objective of this 
study is to determine the effect of the FDA black box warning on ESA use pat-
terns and associated outcomes in insured, low-income cancer patients in South 
Carolina. MethOds: The merged South Carolina Central Cancer Registry-Medicaid 
dataset was used to determine the trend of ESA use from 2001-2010. Female Breast, 
Colorectal and Non-Small Cell Lung cancer patients were identified from the reg-
istry. Of those, their chemotherapy status was identified along with ESA use from 
Medicaid medical claims. The major outcome measures were claims for use of ESAs 
after chemotherapy and the blood transfusion rate. Logistic regression was used as 
a quantitative method to determine if the likelihood of receiving ESA treatment was 
reduced after FDA black box warning. Results: Among 1,645 patients treated with 
chemotherapy from 2002-2010, the proportion of chemotherapy patients receiving 
ESAs decreased from 56.47 % before the black box warning to 23.16% after black box 
warning (p < 0.001). The blood transfusion rate per year during 2002-2007 remained 
around 10-15% and increased to 31% in 2009. The likelihood of ESA use was reduced 
by 63% after black box warning issued by FDA after adjusting for demographic and 
clinical variables. cOnclusiOns: The black box warning may have been effective 
in reducing overall ESA utilization in cancer patients taking chemotherapy.
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to reimbursements, causing a significant growth in costs. Expenses for oncology in 
2003-2011 increased by 718% (from € 15.4 million to € 125.7 million). In December 
2011, a cost/QALY threshold was introduced to legislation, creating a barrier to 
the inclusion of oncology drugs to the Reimbursement list. Following adoption of 
this legislation, of the 12 drugs registered by the EMA, only 3 oncology drugs were 
included to the List during 2012-2014. Uncategorized drugs are available only for a 
limited number of patients by way of individual exceptions, or by participation in 
clinical trials. cOnclusiOns: In Slovakia, the willingness to pay for an additional 
unit of health was anchored in legislation, which greatly limited the availability of 
innovative oncological treatment. The health system in Slovakia needs to intro-
duce efficient and transparent mechanisms that enable the treatment of oncology 
patients in line with the latest medical findings, while keeping expenses for treat-
ment within economic possibilities.
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Objectives: Across geographies, approval, pricing and reimbursement of phar-
maceuticals take place under varying timelines with different outcomes. There 
are some countries that may obtain access to new pharmaceuticals through early 
access schemes. Breakthrough and innovative products that are thought to have a 
profound impact on current standard of care are often eligible for quicker routes to 
access. This research sought to investigate how these schemes worked, where they 
were prevalent, and the outcomes of such schemes. MethOds: The research was 
conducted through in-depth interviews with payers and clinicians across 10 EMEA 
markets. Results: Of the 10 markets studied, 5 countries were identified to have 
either easier or quicker routes to access for new biopharmaceuticals (e.g., ATU in 
France and Algeria, law 648/96 in Italy, non-formulary access in Saudi Arabia, and 
the “white list” in Norway). Most often, these routes were reserved for products with 
orphan indications or products that were believed to significantly impact current 
standard of care. If pharmaceutical companies opt for the streamlined route, there 
are often significant restrictions imposed on the product, as well as a reduction 
in volume. If companies elect for the standard route to approval and reimburse-
ment, the review process is often more rigorous, however, the decision is likely 
more permanent and the volume of product is larger. Frequently, if products opt 
for the faster route to access, this will serve as additional evidence for getting the 
product reimbursed at a later date for use in a wider population. cOnclusiOns: 
New pharmaceutical products that are likely to dramatically change the treatment 
landscape or are active in orphan diseases should take advantage of these schemes. 
Physicians grasp at the opportunity to use efficacious products as early as possible 
and companies need to leverage the opportunity for streamlined access to products.
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Objectives: Lung cancer has a continuously bad prognosis in terms of survival 
and quality of life, usually because of late detection of malignancies. Given an 
expected increase in the incidence, overall mortality will increase. Early detec-
tion and efficient diagnostic planning may offer additional gain in survival. The 
diagnostic pathway for patients with suspected lung cancer is characterized by a 
cascade of different imaging and diagnostic modalities. The main objective of this 
study is to estimate the health economic impact of diagnostic procedures and the 
expected gain by volume-doubling time on low-dose CT as biomarker in suspected 
lung cancer (NELSON protocol). MethOds: A state-transition model is created to 
simulate the pathway of lung cancer diagnostic procedures, including x-ray, diag-
nostic CT, PET-CT, bronchoscopy, mediastinoscopy and more. Hospital registries 
and data from the National Cancer Registry were used to estimate the amount of 
diagnostic procedures in a cohort of lung cancer patients. Systematic literature 
search was performed to estimate the diagnostic performance of different modali-
ties. Patient cohort is defined and the pre-test probability for malignancy is esti-
mated through the Swensen criteria. Probabilistic sensitivity analysis is performed 
using Monte Carlo Simulations. Results: Diagnostic procedures for patients with 
suspected lung cancer can count up to almost € 3000 per patient. Pathway was 
modeled in a microsimulated cohort through Swensen criteria, leading to a mean 
chance of malignancy of 40%. Costly steps in the pathway include cervical medi-
astinoscopy and mutation analysis. Inclusion of NELSON protocol can lead to a 
reduction in costs. Decision making per patient can reduce overuse of diagnostic 
modalities. cOnclusiOns: The diagnostic procedure for suspected lung cancer 
patients is a costly pathway and can be improved with use of the NELSON screening 
protocol or personalized selection of diagnostic procedures.
PCN231
how suCCessful haVe PediatriC iNVestigatioN PlaNs beeN iN 
stimulatiNg researCh for PediatriC CaNCers?
Miller K.L.
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Objectives: The European Pediatric Medicine Regulation was created in 2007 to 
encourage further drug development for pediatric diseases, by requiring pharma-
ceutical companies to submit pediatric investigation plans (PIPs) when submitting 
the marketing application for a new drug. The objective of this study was to deter-
mine how successful this legislation had been in stimulating research in pediat-
